Assessing hepatitis B virus infectivity in blood components following pathogen reduction using a human hepatocyte model
Transfusion · 2025
DOI: 10.1111/trf.18357 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transfusion, 2025. Verfasst von Bryan J Visser und 7 weiteren Autor:innen. Beteiligte Einrichtung: Office of Blood Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA. Hauptthemen laut MEDLINE: Hepatocytes, Hepatitis B virus, Hepatitis B, Blood Safety. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: U.S. Food and Drug Administration.
Abstract (Originalsprache)
Background
Pathogen reduction technologies (PRTs) have the potential to reduce the risk of emerging transfusion transmissible infections. Evaluating PRT activity against hepatitis B virus (HBV) presents some unique challenges due to the lack of robust model systems. Surrogate viruses (e.g., duck HBV) can be used, but may differ from the human pathogen in ways that influence susceptibility to a given PRT.
Methods
Whole blood (WB) collected from volunteers was spiked with human plasma from deferred HBV‐positive donors. Spiked WB was then treated with the nucleic acid crosslinking compound S‐303 or left untreated. Additional physical and chemical treatments were also assessed. Plasma prepared from the spiked WB was used to inoculate human hepatocyte cultures isolated from chimeric mice with humanized livers. Culture medium was monitored over time for hepatitis B surface antigen (HBsAg) and viral DNA. Cell lysates were analyzed for evidence of covalently closed circular (ccc) DNA.
Results
The culture system faithfully measured infectious HBV in blood components. S‐303 treatment of HBV‐spiked WB prevented infection of hepatocyte cultures, as monitored by HBsAg expression, at concentrations as low as 0.125 mM of S‐303 or with incubation times as short as 1 h. Additionally, S‐303 treatment prevented the accumulation of T5 exonuclease‐resistant HBV DNA in inoculated hepatocytes, suggesting that S‐303 prevents establishment of HBV cccDNA.
Conclusion
This model mimics transfusion transmission by using donor‐derived HBV and mouse‐passaged human hepatocytes, allowing evaluation of the efficacy of different PRTs against authentic human HBV isolates. We found S‐303 to be a potent inactivator of HBV.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Office of Blood Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA.
- Cerus Corporation, Concord, California, USA.
ORCID-Profile: Carlos H Villa, David R McGivern
Förderung
- U.S. Food and Drug Administration
Zitieren
APA
Visser, B. J., Biswas, S., Eltahan, R., Fares-Gusmao, R., Yegneswaran, S., Mufti, N., Villa, C. H., & McGivern, D. R. (2025). Assessing hepatitis B virus infectivity in blood components following pathogen reduction using a human hepatocyte model. Transfusion. https://doi.org/10.1111/trf.18357
Vancouver
Visser BJ, Biswas S, Eltahan R, Fares-Gusmao R, Yegneswaran S, Mufti N, et al. Assessing hepatitis B virus infectivity in blood components following pathogen reduction using a human hepatocyte model. Transfusion. 2025. doi:10.1111/trf.18357
BibTeX
@article{Visser2025,
author = {Visser, Bryan J and Biswas, Santanu and Eltahan, Rana and Fares-Gusmao, Rafaelle and Yegneswaran, Subramanian and Mufti, Nina and Villa, Carlos H and McGivern, David R},
title = {Assessing hepatitis B virus infectivity in blood components following pathogen reduction using a human hepatocyte model},
journal = {Transfusion},
year = {2025},
doi = {10.1111/trf.18357}
}
EUVIMED